
[Federal Register Volume 76, Number 73 (Friday, April 15, 2011)]
[Notices]
[Page 21381]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-9153]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2009-E-0241]


Determination of Regulatory Review Period for Purposes of Patent 
Extension; ATRYN; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice 
that appeared in the Federal Register of March 21, 2011 (76 FR 15323). 
The document announced the determination of the regulatory review 
period for ATRYN. The document was published with an incorrect docket 
number. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Joyce Strong, Office of Policy, 
Planning and Budget, Food and Drug Administration, 10903 New Hampshire 
Ave., Bldg. 32, rm. 3208, Silver Spring, MD 20993-0002, 301-796-9138.

SUPPLEMENTARY INFORMATION: In FR Doc. 2011-6509, appearing on page 
15323, in the Federal Register of Monday, March 21, 2011, the following 
correction is made:
    1. On page 15323, in the first column, in the Docket No. heading, 
``[Docket No. FDA-2010-E-0241]'' is corrected to read ``[Docket No. 
FDA-2009-E-0241]''.

    Dated: April 8, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-9153 Filed 4-14-11; 8:45 am]
BILLING CODE 4160-01-P


